Company Analysis
Sign in

Fulcrum Therapeutics, Inc. (FULC)

Nasdaq: FULC · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.2
◀ Past 4.7● Present 6.2▶ Future 4.7
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$0.00-100.0%
Net income-$74.9M-670.0%
Earnings per share$-1.18-637.5%
Operating cash flow-$60.1M-2608.1%
Cash$198M+239.3%
Debtn/a
Shareholders’ equity$349M+43.6%
Shares, diluted63.4M+2.2%
Return on equity-21.5%
The recordfrom its filings
Filings in 202668
Newest filingNov 12 · 10-Q
Annual reportFeb 24, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$800,000
Insider buys, 12 months$0.00
Patents granted8
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$76.3MCash from operations -$65.0Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form 425
Merger communication
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton FULC · research, not advice